Kenya

in page functions
[French]
Kenya
Total population (2017) 48,466,763
Birth cohort (2017) 1,601,353
Surviving Infants (surviving to 1 year per year, 2017) 1,523,809
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 36/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 49/1000
World Bank Index, IDA (2015) 3.82
Gross Nation Income (per capita US$, 2015) 1,340
Co-financing group (2018) Preparatory transition
No. of districts/territories (2016) 47

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Kenya

Type of support

Approvals

2001-2022 (US$)
(28 Mar 2018)

Commitments

2001-2022 (US$)
(28 Mar 2018)

Disbursements

2000-2018 (US$)
(28 Mar 2018)

% Disbursed

(28 Mar 2018)
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Total $454,329,467 $489,086,188 $457,109,349
Cash Support (CASHSUPP) $348,000 $348,000 $145,000 42%
Cold Chain Equipment Optimisation Platform (CCEOP) $4,115,870 $4,115,870 $2,295,631 56%
Health system strengthening (HSS 1) $8,328,382 $8,328,382 $8,328,382 100%
Health system strengthening (HSS 2) $9,227,739 $20,339,960 $7,650,320 83%
HPV Demo (NVS) $714,749 $714,749 $269,399 38%
Immunisation services support (ISS) $6,384,766 $6,384,766 $6,384,766 100%
Injection Safety Devices (NVS) $833,500 $1,214,000 $743,553 89%
Injection safety support (INS) $1,129,963 $1,129,963 $1,129,963 100%
IPV (NVS) $4,798,375 $4,798,375 $3,565,311 74%
Measles-Rubella (NVS) $13,513,824 $13,513,824 $13,513,824 100%
Meningitis A - campaign (NVS) $2,470,000 $2,470,000
Meningitis A - operational costs (OPC) $1,714,144 $1,714,144
MR - Operational costs (OPC) $12,332,500 $12,332,500 $12,332,500 100%
Penta (NVS) $169,671,447 $173,073,447 $169,840,440 100%
Pneumo (NVS) $187,080,953 $201,490,453 $201,701,317 108%
Product Switch Grant (PSG) $379,460 $379,460
Rotavirus (NVS) $26,462,921 $31,845,921 $24,356,884 92%
Vaccine Introduction Grant (VIG) $4,282,500 $4,282,500 $4,282,500 100%
Yellow Fever (NVS) $540,374 $609,874 $569,559 105%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Kenya DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2016)

Grade of confidence


N/A
DTP3 - Official country estimates (2016) 78%
M:F sex ratio at birth (2017) 1.03
Household survey: DTP3 coverage for male (2013) 89.60%
Household survey: DTP3 coverage for female (2013) 90.20%
Household survey: Last DTP3 survey (2013) 90%
% districts achieving > 80% DTP3 coverage (2016) 47%
% districts achieving < 50% DTP3 coverage (2016) 0%
MCV WHO/UNICEF estimates (2016) 75%

Breakdown of support

Non-vaccine support Vaccine support
9% 91%
$42,549,062 $414,560,287

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Kenya

03 April 2018

Typhoid vaccination in Nepal

New typhoid vaccine to receive Gavi support

Gavi has earmarked US$ 85 million to fund the introduction of the vaccine in the world’s poorest countries.

21 December 2017

2017 letter

2017: responding to global challenges

Letter from Gavi's CEO, Dr Seth Berkley.

24 October 2017

Aspen statement - Gavi CEO Seth Berkley and Peggy Clark, ED, Aspen Global Innovators Group

Gavi and the Aspen Institute to strengthen health management capacity in developing countries

Malawi will be the first country to benefit from the new partnership .

close icon

modal window here